左心室辅助器件的抗血栓治疗:一个不适合所有
Emmanuelle Scala1,2, Alexandra Othenin-Girard1
1Department of Anaesthesiology, Cardiothoracic and Vascular Anaesthesia, Lausanne University Hospital (CHUV), Lausanne, Switzerland.
Hamostaseologie
|February 19, 2025
概括
左心室辅助器件 (LVADs) 改善了心力衰竭的生存率. 然而,管理出血和凝血风险 (与血液相容性相关的不良事件) 需要个性化策略和持续的研究,以获得更好的患者结果.
科学领域:
- 心血管医学 心血管医学
- 生物医学工程 生物医学工程
- 医疗技术 医疗技术 医学技术
背景情况:
- 全球心力衰竭的流行率不断增加,需要先进的治疗选择.
- 左心室辅助器件 (LVAD) 对于治疗晚期心力衰竭至关重要.
- 技术进步已经将LVAD从脉动式转变为连续流设计,改善了患者的治疗结果.
研究的目的:
- 审查LVAD技术的演变,重点关注如HeartMate 3这样的连续流设备.
- 讨论与LVADs相关的血红相容性相关不良事件 (HRAE).
- 探索当前和新兴的治疗策略,以管理LVAD患者的HRAE.
主要方法:
- 审查LVAD技术发展,从脉动到连续流.
- 对血红相容性相关不良事件 (HRAE) 的分析,包括血栓,中风和出血.
- 检查当前的抗凝血和抗血小板疗法以及新兴的替代治疗方法.
主要成果:
- 连续流动的LVAD,如HeartMate 3,提高了患者的生存率和生活质量.
- 包括血栓,中风和胃肠道出血在内的HRAE仍然是重大的临床挑战.
- 平衡抗凝药以预防血栓并最大限度地降低出血风险至关重要,需要个性化患者管理.
结论:
- 个性化治疗策略对于LVAD接受者来说是必不可少的,因为设备和患者特定的因素.
- 像直接口服抗凝剂和无阿司匹林疗法等新兴疗法在减少HRAE方面表现有前途.
- 在设备设计和药理干预方面的持续研究对于改善LVAD患者的长期结果至关重要.
相关概念视频
Anticoagulant Drugs: Low-Molecular-Weight Heparins
597
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
597
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.1K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.1K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
371
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
371
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
130
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
130


